At a glance
ClinicalIndex Comparison RecordN/ACompleted· 20 enrolled
Drug / intervention
sunitinib malate +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Pilot Study of Neoadjuvant SUNITINIB MALATE (Sunitinib) in Patients With Renal Cell Carcinoma Undergoing Nephrectomy
In Brief
A clinical study evaluating sunitinib malate, neoadjuvant therapy, and 1 other intervention for Kidney Cancer. Completed, enrolled 20 participants across 1 site.
Detailed Summary
RATIONALE: Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Giving sunitinib before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. PURPOSE: This clinical trial is studying the side effects of giving sunitinib before surgery and to see how well it works in treating patients with localized or metastatic kidney cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsKidney Cancer
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)
Timeline
N/ACompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartAug 2007
First PostedFeb 2009
Primary CompletionJul 2009
Study CompletionApr 2010
TodayJul 2026
First PostedFeb 23, 2009
Enrollment StartAug 1, 2007
Primary CompletionJul 1, 2009
Study CompletionApr 1, 2010
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 17.4 years ago
Interventions
sunitinib malatedrug
oral
neoadjuvant therapyprocedure
IV
therapeutic conventional surgeryprocedure
Surgery